GlassScriptPhysician profile
Clifford Joel Molin
NPI 1194707547
$4,188.69
in general payments reported to CMS, 2019-2025
31 companies · $1,473 in 2025
The $1,473 reported for 2025 was more than what 80% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $39.34 · 2021: $98.93 · 2022: $198 · 2023: $712 · 2024: $1,002 · 2025: $1,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,998 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,997.50 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,133.04 | 2019-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $508.99 | 2019-2025 | |
| Pfizer INC. | $369.57 | 2022-2025 | |
| Novo Nordisk INC | $331.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $329.28 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $246.43 | 2023-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $245.63 | 2022-2025 | |
| Astellas Pharma US INC | $160.78 | 2019-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $104.09 | 2019 | |
| Lilly USA, LLC | $103.28 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.76 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $89.87 | 2021-2025 | Farxiga, Airsupra |
| Hologic Sales and Service, LLC | $73.95 | 2023-2025 | Aptima, Thinprep 2000 Processor |
| Axsome Therapeutics, INC. | $61.37 | 2024-2025 | Sunosi |
| Sanofi Pasteur INC. | $50.24 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $41.04 | 2021-2023 | Arexvy, Shingrix |
| Avadel Cns Pharmaceuticals, LLC | $40.21 | 2024-2025 | Lumryz |
| Amarin Pharma, INC. | $32.71 | 2019 | |
| Cvrx, INC. | $26.87 | 2024 | Barostim Neo System |
| Baxter Healthcare | $25.10 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Itamar Medical INC | $19.44 | 2024 | Watchpatone |
| Ethicon US, LLC | $17.27 | 2019 | |
| Exact Sciences Corporation | $17.27 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $15.58 | 2021 | |
| Shield Therapeutics INC | $13.63 | 2025 | |
| Merck Sharp & Dohme LLC | $13.26 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $13.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.05 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifford Molin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.